These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 33086288)
1. Antinociceptive properties of an isoform-selective inhibitor of Nav1.7 derived from saxitoxin in mouse models of pain. Beckley JT; Pajouhesh H; Luu G; Klas S; Delwig A; Monteleone D; Zhou X; Giuvelis D; Meng ID; Yeomans DC; Hunter JC; Mulcahy JV Pain; 2021 Apr; 162(4):1250-1261. PubMed ID: 33086288 [TBL] [Abstract][Full Text] [Related]
2. Discovery of a selective, state-independent inhibitor of Na Pajouhesh H; Beckley JT; Delwig A; Hajare HS; Luu G; Monteleone D; Zhou X; Ligutti J; Amagasu S; Moyer BD; Yeomans DC; Du Bois J; Mulcahy JV Sci Rep; 2020 Sep; 10(1):14791. PubMed ID: 32908170 [TBL] [Abstract][Full Text] [Related]
3. Insensitivity to Pain upon Adult-Onset Deletion of Nav1.7 or Its Blockade with Selective Inhibitors. Shields SD; Deng L; Reese RM; Dourado M; Tao J; Foreman O; Chang JH; Hackos DH J Neurosci; 2018 Nov; 38(47):10180-10201. PubMed ID: 30301756 [TBL] [Abstract][Full Text] [Related]
4. ST-2560, a selective inhibitor of the Na Mulcahy JV; Beckley JT; Klas SD; Odink DA; Delwig A; Pajouhesh H; Monteleone D; Zhou X; Du Bois J; Yeomans DC; Luu G; Hunter JC Br J Pharmacol; 2024 Sep; 181(17):3160-3171. PubMed ID: 38715413 [TBL] [Abstract][Full Text] [Related]
12. Pharmacologic Characterization of LTGO-33, a Selective Small Molecule Inhibitor of the Voltage-Gated Sodium Channel Na Gilchrist JM; Yang ND; Jiang V; Moyer BD Mol Pharmacol; 2024 Feb; 105(3):233-249. PubMed ID: 38195157 [TBL] [Abstract][Full Text] [Related]
13. Analgesic Effects of Topical Amitriptyline in Patients With Chemotherapy-Induced Peripheral Neuropathy: Mechanistic Insights From Studies in Mice. Genevois AL; Ruel J; Penalba V; Hatton S; Petitfils C; Ducrocq M; Principe P; Dietrich G; Greco C; Delmas P J Pain; 2021 Apr; 22(4):440-453. PubMed ID: 33227509 [TBL] [Abstract][Full Text] [Related]
14. Osteoarthritis-dependent changes in antinociceptive action of Nav1.7 and Nav1.8 sodium channel blockers: An in vivo electrophysiological study in the rat. Rahman W; Dickenson AH Neuroscience; 2015 Jun; 295():103-16. PubMed ID: 25818052 [TBL] [Abstract][Full Text] [Related]
15. New aryl and acylsulfonamides as state-dependent inhibitors of Na Zidar N; Tomašič T; Kikelj D; Durcik M; Tytgat J; Peigneur S; Rogers M; Haworth A; Kirby RW Eur J Med Chem; 2023 Oct; 258():115530. PubMed ID: 37329714 [TBL] [Abstract][Full Text] [Related]
16. Challenges and Opportunities for Therapeutics Targeting the Voltage-Gated Sodium Channel Isoform Na Mulcahy JV; Pajouhesh H; Beckley JT; Delwig A; Du Bois J; Hunter JC J Med Chem; 2019 Oct; 62(19):8695-8710. PubMed ID: 31012583 [TBL] [Abstract][Full Text] [Related]
18. No gain, no pain: NaV1.7 as an analgesic target. King GF; Vetter I ACS Chem Neurosci; 2014 Sep; 5(9):749-51. PubMed ID: 25111714 [TBL] [Abstract][Full Text] [Related]
19. Differential modulation of Nav1.7 and Nav1.8 channels by antidepressant drugs. Thériault O; Poulin H; Beaulieu JM; Chahine M Eur J Pharmacol; 2015 Oct; 764():395-403. PubMed ID: 26187311 [TBL] [Abstract][Full Text] [Related]
20. Pharmacologic Characterization of AMG8379, a Potent and Selective Small Molecule Sulfonamide Antagonist of the Voltage-Gated Sodium Channel Na Kornecook TJ; Yin R; Altmann S; Be X; Berry V; Ilch CP; Jarosh M; Johnson D; Lee JH; Lehto SG; Ligutti J; Liu D; Luther J; Matson D; Ortuno D; Roberts J; Taborn K; Wang J; Weiss MM; Yu V; Zhu DXD; Fremeau RT; Moyer BD J Pharmacol Exp Ther; 2017 Jul; 362(1):146-160. PubMed ID: 28473457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]